NCT06026605View on ClinicalTrials.gov

A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Advanced Malignant Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
Unresectable or Metastatic Advanced Solid Tumors
Interventions
DRUG

WTX212A

WTX212A infusion once every 21 days

Trial Locations (1)

310009

RECRUITING

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER